Thomas Schaible - Fortress Biotech Project Disease
| FBIO Stock | USD 1.72 0.03 1.71% |
Insider
Thomas Schaible is Project Disease of Fortress Biotech
| Phone | 781 652 4500 |
| Web | https://www.fortressbiotech.com |
Fortress Biotech Management Efficiency
The company has return on total asset (ROA) of (0.3641) % which means that it has lost $0.3641 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.3964) %, meaning that it created substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Alexandra MD | Avenue Therapeutics | 58 | |
| Robert Renninger | Athira Pharma | 41 | |
| David Jin | Fortress Biotech Pref | 33 | |
| Xiaoqin MD | Avenue Therapeutics | 49 | |
| Aimee MD | Cabaletta Bio | N/A | |
| Robert Coutts | Achilles Therapeutics PLC | 41 | |
| David Jin | Avenue Therapeutics | 34 | |
| BSc FRCPath | Achilles Therapeutics PLC | 59 | |
| Julie Rathbun | Athira Pharma | N/A | |
| MBA MBA | Athira Pharma | 54 | |
| Sergio Quezada | Achilles Therapeutics PLC | 49 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
| Anup MBA | Cabaletta Bio | 48 | |
| Bren Kern | Eyenovia | 44 | |
| Rachel MBA | Athira Pharma | 51 | |
| Laxminarayan Bhat | Reviva Pharmaceuticals Holdings | 60 | |
| Iraj Ali | Achilles Therapeutics PLC | 50 | |
| Alexander Lobo | Eyenovia | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Steven MD | Cabaletta Bio | 64 | |
| Samik MD | Cabaletta Bio | N/A | |
Management Performance
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.36 |
Fortress Biotech Leadership Team
Elected by the shareholders, the Fortress Biotech's board of directors comprises two types of representatives: Fortress Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fortress. The board's role is to monitor Fortress Biotech's management team and ensure that shareholders' interests are well served. Fortress Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fortress Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lindsay Rosenwald, Chairman of the Board and Presidentident, CEO | ||
| Samuel Berry, General Secretary | ||
| Robyn Hunter, Ex Officer | ||
| Michael Esq, Executive Director | ||
| Thomas Schaible, Project Disease | ||
| George Avgerinos, Sr. VP of Biologics Operations | ||
| David Jin, CFO Development |
Fortress Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Fortress Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.36 | ||||
| Profit Margin | (0.49) % | ||||
| Operating Margin | (1.69) % | ||||
| Current Valuation | 60.99 M | ||||
| Shares Outstanding | 27.56 M | ||||
| Shares Owned By Insiders | 21.20 % | ||||
| Shares Owned By Institutions | 14.46 % | ||||
| Number Of Shares Shorted | 3.69 M | ||||
| Price To Earning | (2.92) X |
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Fortress Stock
Moving against Fortress Stock
| 0.56 | DMAC | DiaMedica Therapeutics | PairCorr |
| 0.56 | DVAX | Dynavax Technologies | PairCorr |
| 0.55 | VALN | Valneva SE ADR | PairCorr |
| 0.55 | VIGL | Vigil Neuroscience | PairCorr |
| 0.5 | DTIL | Precision BioSciences Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.